The T cell antigen receptor: the Swiss army knife of the immune system

M. Attaf, M. Legut, D. K. Cole and A. K. Sewell
Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK

Summary

The mammalian T cell receptor (TCR) orchestrates immunity by responding to many billions of different ligands that it has never encountered before and cannot adapt to at the protein sequence level. This remarkable receptor exists in two main heterodimeric isoforms: αβ TCR and γδ TCR. The αβ TCR is expressed on the majority of peripheral T cells. Most αβ T cells recognize peptides, derived from degraded proteins, presented at the cell surface in molecular cradles called major histocompatibility complex (MHC) molecules. Recent reports have described other αβ T cell subsets. These 'unconventional' T cells bear TCRs that are capable of recognizing lipid ligands presented in the context of the MHC-like CD1 protein family or bacterial metabolites bound to the MHC-related protein 1 (MR1). γδ T cells constitute a minority of the T cell pool in human blood, but can represent up to half of total T cells in tissues such as the gut and skin. The identity of the preferred ligands for γδ T cells remains obscure, but it is now known that this receptor can also functionally engage CD1-lipid, or immunoglobulin (Ig) superfamily proteins called butyrophilins in the presence of pyrophosphate intermediates of bacterial lipid biosynthesis. Interactions between TCRs and these ligands allow the host to discriminate between self and non-self and co-ordinate an attack on the latter. Here, we describe how cells of the T lymphocyte lineage and their antigen receptors are generated and discuss the various modes of antigen recognition by these extraordinarily versatile receptors.

Keywords: CD1, MHC-I, MHC-II, MHC-Ib, MR1, T cell, T cell receptor, αβ TCR, γδ TCR

Introduction

Immune surveillance by T lymphocytes is critical for the immune integrity of all jawed vertebrates and is imposed through an intricate armoury of functions that eliminate pathogen-infected and neoplastic cells. The T cell pool consists of several functionally and phenotypically heterogeneous subpopulations. T cells are broadly classified as αβ or γδ according to the somatically rearranged T cell receptor (TCR) they express at their surface.

αβ T cells are by far the most abundant and the best-characterized circulating T cells. Most αβ T cells recognize peptides from degraded proteins bound to major histocompatibility complex (MHC) molecules at the cell surface. These peptide-MHC (pMHC)-recognizing T cells were the first to be described [1]. T cells that respond to pMHC are said to be 'conventional'. However, a significant fraction of the αβ T cell pool consists of rarer T lymphocytes that do not recognize pMHC. These 'unconventional' αβ T cells include: (i) mucosal-associated invariant T (MAIT) cells that display limited diversity and are involved in antibacterial immunity [2,3]; (ii) invariant natural killer T (iNK T) cells; and (iii) germline-encoded mycolyl-reactive (GEM) T cells. iNK T and GEM T cells are dedicated to recognition of glycolipids in the context of CD1d and CD1b, respectively [4,5]. Other T cells are believed to recognize lipid antigens in the context of CD1a and CD1c, but these subsets have not been well characterized, or named, at the time of writing.

γδ T cells are also grouped as being 'unconventional', as they are not MHC-restricted and do not appear to recognize...
peptide antigens. One to 10% of circulating T cells express a γδ TCR, but this fraction is considerably higher in epithelial tissues. These tissues form the main portal of entry for pathogens, suggesting an important role of γδ T cells as early immune sentinels. Murine knock-out studies have demonstrated that γδ T cells have a clear role in pathogen clearance and tumour surveillance [6]. Some T cells express a δ/αβ TCR hybrid. This is because the recombination mechanism used to generate TCR chains operates on the same locus for TCR-δ and TCR-α. Thus, some gene segments within the locus can, in some instances, be involved in the generation of TCR chains that are partially α and partially δ and are able to pair with canonical TCR-β chains [7]. These so-called δ/αβ T cells constitute a significant proportion of T cells that recognize the CD1d-α-galactosylceramide (αGalCer) complex [7]. Other hybrid TCRs further blur traditional segregation into αβ and γδ TCRs, as Vγ1β, Vβγ, Vββ, Vβγ and Vγδ TCR chains have been described, with or without the inclusion of DB and Dδ segments. Many of these combinations follow the 12/23 rule of V–(D)–J recombination, are transcribed into full transcripts and translated into hybrid proteins [8]. The antigens recognized by T cells bearing these non-canonical TCR chains remain unknown, although a subset of Vγ (Dβ) Jβ TCRs are reported to be MHC-restricted [9].

Despite the functional and phenotypical differences between subsets, all T cells arise from the same precursors and share their early differentiation history. Thymic progenitor cells seed the thymus from the fetal liver or adult bone marrow. In the thymus, these progenitors enter a complex differentiation programme which leads to irreversible acquisition of T cell identity and expression of clonally distributed, variegated TCRs. In this review, we describe the mechanisms through which MHC-restricted and MHC-independent TCRs are generated and discuss recognition of antigen by distinct T cell subsets. We also re-examine recent findings on the more ‘unconventional’ subsets.

**Generation of diversity and thymic selection**

TCR diversity is generated somatically by gene rearrangement, a process that allows a vast array of different receptors to be produced from a limited set of genes. At the TCR-α locus (tra), discrete variable (V) and junctional (J) gene segments are recombined and juxtaposed to a constant (C) segment (Fig. 1a). Recombination at the TCR-β locus (trb) is similar, but includes an additional diversity (D) segment and one of two C segments can be appended to the rearranged TCR-β chain (Fig. 1b). The variability of TCRs is confined predominantly to three short hairpin loops on each chain, called complementarity determining regions (CDR). Collectively, the six CDR loops sit at the membrane-distal end of the TCR extracellular domain to form the antigen-binding site (Fig. 2a).

The variable CDR1 and 2 loops are encoded in the germ-line by the T cell receptor alpha variable (TRAV) and T cell receptor beta variable (TRBV) gene segments. By contrast, the hypervariable CDR3 loops are generated by random deletion and addition of template and non-template nucleotides at the junction between recombining V, (D) and J gene segments (Fig. 2b). Polymorphism in the tr loci could add yet further diversity to the potential TCR repertoire at the population level [12]. Theoretically, gene rearrangement by V–(D)–J recombination alone can produce ~10^{18} TCRs in humans [13] and ~10^{15} TCRs in the mouse [14]. γδ TCRs are also generated by V–(D)–J recombination (Fig. 1c,d). The TCR-δ chain is thought to be by far the most diverse TCR chain due to the inclusion of multiple D segments, which can be translated in any reading frame (Fig. 2b). Thus, the theoretical number of different γδ TCRs that could be produced is potentially much greater than for the αβ TCR.

The quasi-random process of generating αβ TCRs described above has the capacity to generate receptors that are inept at recognizing self-MHC molecules and receptors that could be autoreactive. Thymic selection ensures that only T cells bearing a TCR that recognizes self-peptides in the context of self-MHC receive a survival signal. The majority of thymocytes do not receive this signal. Cells that express TCRs that cannot recognize self-pMHC are unlikely to be useful for recognizing foreign peptides. These cells do not receive a survival signal through their TCR and are said to ‘die by neglect’. At the other extreme, thymocytes that bear TCRs that react strongly to self-pMHC have the capacity to be autoreactive and are culled through a process of negative selection. Together, positive and negative selection ensure that only those αβ T cells that are restricted to recognizing self-pMHC within a low affinity range can populate the periphery. Thus, the thymic environment allows the generation of a pool of αβ T cells that are self-restricted, but not self-reactive [15].

Much less is known about selection of other, MHC-independent, T cell subsets. Invariant (type I) NK T cells are selected on CD1d-expressing CD4^+CD8^+ double-positive thymocytes and acquire effector function before exiting the thymus [16–18]. Selection of MAIT cells has been shown recently to require MR1 expression on double-positive thymocytes [19]. Commitment to the γδ T cell fate is thought to be a TCR-dependent process whereby strong γδ TCR signals induce γδ commitment and weak pre-TCR signals, in the absence of γδ TCR signalling, instruct thymocytes to initiate tra rearrangement [20]. This model mirrors classic positive selection via the αβ TCR and suggests that γδ T cells may also need to encounter a cognate ligand in the thymus. Indeed, CD73 is up-regulated as a result of γδ TCR activation in the thymus. As CD73 is expressed by the majority of peripheral γδ T cells, ligand recognition in the thymus appears...
to be a common occurrence during γδ T cell development [21]. However, potential ligands for γδ T cells are largely unknown. Skint-1 is the only known ligand required for maturation of Vγ51δ1 dendritic epidermal γδ T cells in the mouse, although its role in selection remains controversial [22]. Interestingly, a study of murine T10/T22-reactive γδ T cells has indicated that, in contrast to αβ T cells, ligand recognition by the γδ TCR imprints effector function on the γδ T cell pool, but not antigen specificity [23]. Overall, γδ T cell selection is poorly understood and the identity of potential positive selection ligands for γδ TCRs continues to be a matter of debate.

**Conventional, pMHC-restricted T cells**

The cardinal feature of αβ T cells is the recognition of peptides derived from self and foreign proteins in the context of self-MHC molecules. The mhc locus was first described more than half a century ago as the set of genes which determine the outcome of tissue transplantation in congenic mice. It is now clear that the products of the mhc have evolved to allow T cells to perform highly specific functions which are crucial to adaptive immunity and host defence as a whole. The mhc locus is the most gene-dense and the most polymorphic region known to date, with more than 12 000 different alleles already
Polymorphism at the \( \text{mhc} \) ensures diversity in peptide presentation at the population level. There are two types of classical MHC molecules: MHC class I (MHC-I) and MHC class II (MHC-II). There are three classical human MHC-I genes [human leucocyte antigen (HLA)-A, -B and -C]. These genes encode a membrane-spanning \( \alpha \)-chain associated with the non-polymorphic \( \beta_2 \) microglobulin (\( \beta_2\text{m} \)) protein (Fig. 3a).

Polymorphism is confined mainly to the membrane-distal \( \alpha_1 \) and \( \alpha_2 \) domains, while the \( \alpha_3 \) domain is largely invariant. The human MHC-II genes (DP, DQ and DR) encode two distinct polymorphic \( \alpha \) and \( \beta \)-chains. Each chain folds into a membrane-distal polymorphic domain followed by a membrane-proximal immunoglobulin (Ig)-like domain (Fig. 3d) [37]. The peptide-binding cleft of both MHC-I and MHC-II consists of two anti-parallel \( \alpha \)-helices forming a channel in which the peptide can bind in an extended conformation on a platform of eight anti-parallel \( \beta \)-pleated sheets. Specific peptide-binding pockets in the base of this cleft vary between different MHC alleles [38]. The binding affinity for MHC differs between peptides according to their primary sequence. A given peptide will, at best, bind a limited set of MHCs. Reciprocally, any MHC allele can only accommodate a small fraction of the peptide collection derived from a given protein.

Conventional \( \alpha \beta \) TCR ligands

MHC-I molecules are expressed on nearly all nucleated cells and present peptides derived from endogenous proteins, allowing T cells to interrogate the internal proteome by scanning the surface of the target cell. MHC-II molecules differ from MHC-I in that they predominantly present peptides derived from exogenous proteins and are expressed primarily on professional antigen-presenting cells. Despite the similarities in overall conformation (Fig. 3), MHC-I and MHC-II present peptides in a distinct manner governed by the configuration of the peptide-binding cleft. Polymorphic residues define the size and chemical properties of the binding pockets within the cleft and therefore the peptide collection that can be accommodated by a given MHC-I molecule. The closed

---

Fig. 2. Structure of T cell receptor (TCR) proteins and mRNA. (a) \( \alpha \beta \) [Protein Data Bank (PDB): 3HG1] [10] and \( \gamma \delta \) (PDB: 1HXM) [11]. TCRs adopt similar tertiary structures that position the complementarity-determining regions (CDR) loops at the membrane distal end of the molecules. Together the six CDR loops form the antigen binding site. (b) The mRNA structures show that for each chain CDR1 and CDR2 are encoded in the germline. CDR3 is the product of junctional diversity at V-J joins of T cell receptor (TCR)-\( \alpha \) and TCR-\( \gamma \) chains and V-D-J joins in TCR-\( \beta \) and TCR-\( \delta \) chains. CDR3 is consequently hypervariable. The colour code adopted for the CDR loops is maintained throughout this paper. The areas coloured in grey represent the constant and variable domains of the TCRs (not including the hypervariable CDR loops).
conformation of the MHC-I α1α2 binding cleft (Fig. 3b) restricts the length of peptides that can be accommodated. MHC-I molecules typically bind peptides of eight to 10 amino acids in length, but longer peptides have been observed in some instances [39]. Because the MHC-I peptide-binding groove is closed at both ends, long peptides bulge out (Fig. 3c), exposing peptide side chains for direct interaction with the TCR [39]. Curiously, our own recent studies have shown that MHC-I restricted TCRs appear to be predisposed to bind peptides of a defined length [27]. In contrast, the MHC-II peptide-binding groove is an open-ended conformation (Fig. 3e) which allows the binding of N- and C-terminally extended peptides of up to 30 amino acids in length (Fig. 3f).

TCR recognition of pMHC

MHC restriction is a defining characteristic of ‘conventional’ αβ T cells. Although MHC restriction was described more than 30 years ago, the molecular forces...
driving this interaction are still fiercely debated. Structural analyses of TCRs in their free and MHC-bound states have established that the TCR–pMHC interaction conforms to some ‘rules of engagement’. Indeed, most TCRs bind pMHC in a diagonal or nearly orthogonal orientation relative to the long axis of the MHC peptide-binding groove (Fig. 4a and b) [37]. This conserved docking strategy, together with the observation that 20% of the pre-selection TCR repertoire is MHC-specific [42], has led to the idea that TCRs are genetically ‘hard-wired’ for MHC recognition [23–45]. These rules fit conveniently with the observation that the germline-encoded CDR1 and 2 loops often contact the MHC α-helices, whereas the somatically rearranged CDR3α and CDR3β loops contact the peptide (Fig. 4c).

Recently, however, Stadinski et al. [47] challenged the germline theory by demonstrating that the putative ‘interaction codons’ in a murine TCR-β chain were not strictly conserved, but were largely dependent on the identity of the partner TCR-α chain. Mutational studies on MHC alleles also suggest that TCR–pMHC interactions allow for substantial plasticity within the confines of a common binding and orientation system [48]. A murine study in which CDR1 and CDR2 were randomized in vivo in the context of a fixed CDR3 failed to show preferential selection for the wild-type CDR1 and 2 sequences, contradicting the idea of TCRs being genetically ‘biased’ towards MHC ligands [49]. It remains possible that the semi-conserved angle and polarity of TCR–pMHC interaction is required for the correct orientation of intracellular signalling domains, the positioning of the co-receptor binding site on MHC relative to the TCR or imposed by extracellular sites of glycosylation, as indicated by the

---

**Fig. 4.** T cell receptor (TCR)–peptide-major histocompatibility complex (pMHC) structures. MHC molecules (in grey) and peptide (in red sticks) are overlaid with the docking footprints of the individual complementarity-determining regions (CDR) loops of the cognate αβTCR. The coloured footprints correspond to the colours of the CDR loops shown in Fig. 2. (a) Structure of MHC-I molecule HLA-A*0201 presenting the immunodominant GLCTLVAML peptide from Epstein–Barr virus (EBV) [Protein Data Bank (PDB): 3O4L] [40]. The coloured footprint shows how the CDR loops of the A501 TCR sit on the pMHC complex. This complex adopts a canonical conformation where the germline-encoded CDR1 and 2 loops contact mainly the MHC and the hypervariable CDR3 loops sit over the peptide. (b) Structure of the MS2-3C8TCR docked on the MHC class II molecule human leucocyte antigen (HLA)-DR4. Here, HLA-DR4 presents a peptide from myelin basic protein (PDB: 3O6F) [41]. (c) Overlay of all MHC-I (grey cartoon and surface)-restricted TCRs (multi-coloured) in which co-complex structures have been solved. All complexes were aligned on the MHC-I molecule to demonstrate the flexible nature of TCR–pMHC binding.
Our recent studies show that TCR-peptide specificity overrides affinity-enhancing TCR–pMHC interactions to suggest that TCR CDR3 loops might need to ‘accept’ peptide prior to TCR engagement the MHC component of the ligand [51]. Further work is required in order to dissect the sequence of molecular events involved in TCR–pMHC binding.

An alternative to the germline theory of MHC restriction suggests that recognition of MHC-restricted ligands is the result of a selection process through which the peripheral repertoire is enriched with MHC-specific TCRs and purged of MHC-independent TCRs. In a series of studies involving MHC-I, MHC-II and co-receptor deficient-mice (referred to as ‘quad-deficient’ mice), it was shown that the selection of MHC-specific TCRs was strictly governed by the T cell co-receptors CD4 and CD8. CD4 and CD8 act as antigen co-receptors by binding to invariant regions of the MHC-II and MHC-I, respectively, at sites distinct from the TCR docking platform (Fig. 5). The cytoplasmic tail of the co-receptor binds to the protein tyrosine kinase Lck, which mediates key membrane-proximal phosphorylation events during T cell activation and selection. Singer and colleagues [53] first showed that the deletion of both co-receptors allowed selection of CD41 and CD81 T cells to take place on an MHC-deficient background. The authors worked on the premise that co-receptor-independent signalling can occur and is initiated by non-MHC ligand binding to the TCR, akin to cross-linking antibodies. By contrast, in the presence of co-receptors, which sequester all the available Lck needed for signalling, TCR signalling can be triggered only by MHC ligands. Thus, in the ‘quad-deficient’ mouse, non-MHC ligands can induce thymic selection of MHC-independent T cells – T cells which would otherwise die by neglect in a normal thymus [54–56]. Reports of MHC-independent ligands for αβ T cells are scarce in the literature, although a number of examples have been observed in the mouse [57] and in humans [58,59]. The existence of MHC-independent αβ TCRs in the periphery further supports the notion that MHC restriction is a TCR-extrinsic feature imposed on developing thymocytes through thymic selection.

**αβ TCR cross-reactivity**

As described above, the mhc locus is an example of extreme polymorphism. The vast majority of polymorphic residues in MHC proteins cluster around the peptide-binding cleft to suggest that this diversity is upheld to expand the variety of peptides that can be displayed to the immune system [38]. The TCR must recognize peptides presented by all these variants. Beyond this, effective T cell immunity requires the TCR repertoire to recognize virtually any foreign peptide that can bind to host MHC molecules as a failure to recognize all possible foreign peptides would leave ‘blind spots’ that could be exploited by pathogens [60]. Unlike the B cell receptor, the protein sequence of the TCR is fixed and never undergoes affinity maturation, so the TCRs expressed on existing naive T cells must be capable of responding to all alien antigens, despite never having encountered them before and being unable to adapt to them. The size of this task becomes apparent once it is realized just how many potential foreign peptides there are. This major evolutionary challenge has been met by enabling each
TCR to interact with many – sometimes millions – of individual peptides bound in the groove of a single MHC [13,61]. TCRs are further capable of engaging peptides presented by different foreign MHC alleles to promote alloreactivity. This enormous receptor plasticity is bestowed via a number of different mechanisms, as TCR binding can vary from being rigid and very focused [62] to being flexible in terms of both binding register and individual CDR loops (Fig. 6). It is also possible that the ability of T cells to respond to different TCR ligands could be varied during T cell development. TCR engagement in the presence of inhibitory signals is likely to dampen the number of ligands, whereas co-stimulatory signals would be expected to generate a greater level of T cell sensitivity and might increase the number of ligands that could be recognized (Fig. 7a,b). The co-receptors, CD8 and CD4, fall into a class of their own by co-engaging the pMHC ligand, thereby generating capacity for the molecules to alter which TCR ligands a T cell can respond to [66,67] (Fig. 7c).

Implications of T cell cross-reactivity

It is becoming apparent that effective immune cover requires that each TCR must allow the T cell that bears it to respond to a large array of different peptide ligands [60]. This extensive receptor cross-reactivity has a number of important consequences. First, it allows a relatively small number of TCRs (~25 million [68]) to provide effective immune cover for a vastly greater number of theoretical foreign peptides that could be encountered. Extensive T cell cross-reactivity also ensures that far fewer T cells are required to scan a cell displaying a foreign peptide before one reacts to this peptide, thus ensuring a more rapid response time. The corollary of far-reaching TCR cross-reactivity is that each peptide will be
recognized by several different receptors (i.e. T cell responses are polyclonal). Escape from a polyclonal T cell response represents a far greater challenge for pathogens that can vary their antigens, as a mutation that escapes from one TCR may still be recognized by a different TCR. Heterologous immunity, where a single T cell can respond to several infections, is a further important consequence of individual TCRs being capable of responding to multiple peptides [69]. Once it is realized that T cells can respond to many different peptides it should come as little surprise that there are pre-existing populations of HIV-specific memory T cells in people who are uninfected with this virus [70]. The extent and implications of T cell heterologous immunity are described in detail elsewhere [13,69]. The advantages of having a broadly cross-reactive T cell repertoire must outweigh the negatives, or the system would have been expected to evolve differently. Nevertheless, it is believed that widely cross-reactive T cells can have detrimental consequences. Most notably, the concept of T cells becoming activated by pathogens and then cross-recognizing self-ligands – a phenomenon known as molecular mimicry [71] – is believed to be the root cause of autoimmune disease (Fig. 8). A further important consequence of TCR binding plasticity is alloreactive recognition of non-self-HLA presenting self-peptide because such recognition causes acute rejection of HLA-mismatched grafted organs [72]. Alloreactive recognition of pMHC by the TCR represents the major barrier to organ transplantation. Most transplants are HLA mismatched and require that the recipient take lifelong immunosuppressive medication, with its associated expense and side effects.

**Therapeutic use of the αβ TCR**

The transfer of TCR genes into recipient host T cells followed by the adoptive transfer of these cells to patients allows the passive transfer of immunity [73]. This strategy can provide a convenient means for breaking tolerance to tumour antigens and has already shown promise in patients with malignant melanoma [74]. As described above, T cell immunity is a compromise where a limited number of receptors are required to provide immune cover for a vastly greater number of potential foreign peptides
peptides bound to self-MHC. This compromise ensures that individual TCR–pMHC interactions are rarely optimal. Recent developments mean that TCRs can now be affinity-enhanced by phage display [75], yeast display [76] and computational design [77,78]. Such enhancement has been used to build immune foresight by selecting TCRs that can recognize all known escape variants of HIV [79]. Enhanced TCRs are particularly useful for cancer immunotherapy, as thymic selection culls T cells whose TCRs strongly recognize self-antigens. This process is presumably responsible for the finding that natural anti-tumour TCRs bind with substantially weaker affinity than anti-pathogen TCRs [80,81]. This leaves cancer-specific T cells at a distinct disadvantage compared to their counterparts that respond to non-self-peptides. The enhancement processes described above can now be used to close the TCR binding affinity gap between optimal anti-pathogen TCRs and weaker anti-tumour TCRs. Enhanced optimal TCRs can then be used in TCR gene therapy for cancer [82]. Such approaches are currently showing great promise. However, as enhanced TCRs have not undergone the rigours of thymic selection, where cells with TCRs that react strongly to self are deleted, they carry an inherent, but small, risk of being autoreactive. A recent trial of a TCR specific for the cancer-specific protein melanoma-associated antigen (MAGE) highlighted the potential problem. When cells with an enhanced MAGE-specific TCR were transfused back into two cancer patients, these patients developed rapid and fatal heart disease. Subsequent studies determined that the modified MAGE-specific TCR was also capable of cross-reacting with an MHC-I-presented peptide from the heart protein titin [83,84]. Despite these teething problems, other trials with other receptors have been successful, and we anticipate that the use of such therapies will become common-place in the next 20 years. Many groups are currently examining the use of various hybrid antigen receptors in T cell therapy. Such strategies are beyond the scope of this review, but have been documented recently elsewhere [85]. Enhanced TCRs have also recently been used as soluble molecules to induce cancer regression [86], thus opening up a further exciting mechanism by which TCRs can be used for therapeutic benefit (Fig. 9). The use of TCRs as soluble ‘drugs’ does not incorporate the same dangers as cell-based TCR therapies, as dosage can be scaled or medication withdrawn if difficulties arise. The potential for commercial use of TCRs has been assessed elsewhere [87].

Unconventional T cells

The list of unconventional T cells that do not recognize pMHC ligands is growing steadily, further demonstrating the versatility of the TCR. Recent discoveries have highlighted the existence of αβ T cells that recognize non-peptide ligands. Approximately 10% of all αβ T cells are now thought to recognize lipid antigens. A further 10% of human αβ T cells appear to recognize bacterial metabolites. αβ TCR recognition of lipids

Many human αβ T cells have been identified recently that respond to non-peptide antigens presented by MHC class I-related molecules from the CD1 protein family [88]. These glycoproteins are ideally suited for presentation of lipid-based antigens to T cells due to the hydrophobic nature of their deep antigen-binding pockets. There are five isoforms of CD1 molecules in humans, CD1a–e, although CD1e is not involved in antigen presentation. The antigen-binding clefts of CD1a–d differ in shape and size permitting the presentation of different lipids to T cells (Fig.10). T cells restricted by the group I CD1 molecules (CD1a–c) are considerably more numeric than CD1d-restricted T cells, but far less is known about these T cells and the TCRs that they
CD1d–lipid complexes bind to TCRs that are expressed by the innate-like NK T cells [93]. CD1d-restricted T cells are divided into two types based on their TCR gene usage and the antigens to which they respond. Human type I NK T cells respond strongly to the lipid α-GalCer. These T cells typically utilize a semi-invariant TCR, and have been termed iNK T cells to reflect this. The type I NK T TCR uses an invariant TCR-α chain (TRA V10/TRA J18) paired with a TRBV25.1-encoded β chain. Type II NK T cells express a broader TCR repertoire and are not activated by α-GalCer. NK T TCR recognition appears to be far more rigid than that observed for conventional recognition of pMHC. Type I NK T TCRs adopt a common footprint on CD1d (Fig. 11a). This recognition has been compared to an innate pattern recognition receptor. Recent type II NK T TCR–CD1d–sulphatide and lysosulphatide complexes have revealed that the mode of type II NK T TCR recognition is different to type I NK T TCR recognition [97]. Type II NK T cells dock orthogonally and over the A0-pocket of CD1d and make a larger binding interface than type I NK T TCRs. The binding mode of type II NK T TCRs is closer to that used by conventional TCR docking on pMHC.

GEM T cells recognize mycobacteria-derived (glyco)-lipids in the context of CD1b, a molecule which has the potential to accommodate the largest and most diverse lipid ligands among the CD1 protein family [90]. Although no ternary structure of a TCR bound to the CD1b–lipid complex has been resolved so far, a recent study suggested that binding of the lipid antigen to CD1b could induce a conformational change of the latter. Thus, the TCR recognition would be mediated not only by the solvent-exposed polar headgroup of the lipid, but also by the rearranged residues from the antigen-presenting molecule [90]. CD1c is also capable of presenting mycobacterial lipids and lipopeptides [98]. Similarly to CD1b, TCR recognition of CD1c seems to be mediated by both the lipid antigen and CD1c residues; however, without showing a common pattern recognised by all TCRs responding to the same antigen [91]. Interestingly, CD1c can also present immunogenic self-derived lipids accumulated in leukaemia cells, contributing to αβ T cell-mediated tumour surveillance [99].

Contrary to CD1b–d, CD1a can bind lipids lacking a polar headgroup. These hydrophobic lipid antigens are then not recognized directly by the TCR, but rather allow CD1a to adapt to a TCR-activating conformation [89] (Fig. 11b). In contrast, lipids containing a polar headgroup can also be bound by CD1a but disrupt the activating conformation of the antigen-presenting molecule, thus abolishing TCR-mediated recognition.

MR1-restricted αβ TCRs

It has been shown recently that MAIT cells recognize intermediates in the riboflavin biosynthesis pathway express. At the time of writing, structures of group I CD1-restricted TCRs in complex with their antigen are only just starting to emerge. It is expected that further structures will appear soon in the literature.
bound to the MHC-like molecule MR1 [100–102]. MAIT cells constitute about 10% of all T cells in humans, so recognition is likely to represent the most dominant of all T cell antigen-specificities. Vitamin B is synthesized by some bacteria and yeast but not by mammals. Thus, such microbial-specific biosynthetic pathways provide a further mechanism that T cells can use to distinguish self from non-self. MAIT TCRs bind to riboflavin precursors and the presenting MR1 molecule (Fig. 11c). Interestingly, MR1 can also present non-activating metabolites belonging to the vitamin B group, namely folic acid derivatives. The invariant TCR-α chain binds MR1 in a conserved, innate-like manner, thus allowing the TCR to interact directly with the activating riboflavin precursor, while no such contact is made if the MR1-bound ligand is a folic acid derivative [95,103]. MAIT cells have set a new paradigm in T cell recognition. As yet it is unclear how many other bacterial metabolites can be recognized by T cells, as a recent study by Corbett et al. [104] showed that MR1 is capable of capturing and presenting unstable intermediates of riboflavin synthesis, which would otherwise be converted into non-activating metabolites. However, it is established that the dominant subset of γδ T cells in human peripheral blood recognize intermediates in the non-mevalonate microbial pathway of isoprenoid biosynthesis, so it remains possible that a sizable fraction of human T cells also target other microbial-specific synthetic pathways.

γδ TCRs

Surprisingly little is known about human γδ T cells or the ligands they recognize. Unlike αβ T cells, γδ T cells exhibit strict tissue-specific localization, which is determined by the identity of the rearranged TCR. This is because gene rearrangement at the trg and trd loci is programmed developmentally and different γδ T cells carrying distinct TCR-γ and TCR-δ rearrangements arise in successive waves that colonize different tissues during embryonic development [105]. The tissue specificity of γδ T cells may also reflect a difference in the expression of γδ TCR ligands. Should this prove true, then γδ TCRs and their ligands might become very useful for tissue
targeting. It remains to be seen whether γδ TCRs can ever bind to pMHC ligands. Nevertheless, structural studies of the complex between a murine γδ TCR and an MHC class I-like molecule T22 (Fig. 11f) indicate that at least some γδ TCRs can bind their ligand in a manner reminiscent of αβ TCR–MHC interactions [96,106].

Most progress with γδ TCRs has been made with the predominant subset of γδ T cells found in human peripheral blood that express a TCR made from the Vγ9 and Vδ2 genes. Vγ9+Vδ2+ T cells have been shown to recognize small pyrophosphate intermediates of the lipid biosynthetic pathway used by some bacteria [107,108]. Notably, pyrophosphate antigens can accumulate in neoplastic cells as well, as a result of metabolic deregulation [109]. While the structure of a Vγ9Vδ2 TCR has been solved [110], there is not yet a structure of this TCR bound to its ligand. Recognition of pyrophosphate ligands requires cellular presentation by a primate cell [111]. This species specificity suggested that pyrophosphate antigens might be presented to Vγ9+Vδ2+ T cells by an MHC-like molecule. Recently the candidate for a pyrophosphate antigen-presenting molecule has been narrowed down to butyrophilin 3A1 (BTN3A1), an immunoglobulin-like molecule encoded in the MHC I locus. Crystallographic studies revealed that pyrophosphate antigens can be bound either in a shallow extracellular pocket of BTN3A1 and presented directly to TCRs [112] or in an intracellular domain, enforcing a TCR-activating conformational change of the presenting molecule [113]. These mechanisms, however, are not necessarily mutually exclusive, as both intra- and extracellular binding of phosphoantigens may be required for efficient TCR recognition.

Fig. 11. Recognition of antigen by ‘unconventional’ T cell receptors (TCRs). (a) Type I natural killer (NK) TCR recognition. The TCR binds CD1d-α-galactosylceramide (αGalCer) in a parallel docking mode. The recognition is markedly different from any known αβ TCR–peptide-MHC (pMHC) interactions [Protein Data Bank (PDB): 3VWK] [94]. (b) Recognition of CD1a-lipid complex. αβ TCR recognizes a permissive conformation of CD1a surface that depends on the nature of the lipid ligand bound by the latter. Contrary to TCR-CD1d structures, no direct interactions between TCR and a lipid ligand bound to CD1a have been observed (PDB: 4X6C) [89]. (c) Mucosal-associated invariant T (MAIT) TCR recognition of MR1. MR1 can present both activating (riboflavin precursors) and non-activating (folic acid precursors) intermediates from vitamin B biosynthetic pathways. The recognition of MR1 is mediated by conserved, invariant residues in an innate-like manner. The activating metabolites directly contact the TCR while no such interactions are observed for the non-activating metabolites (PDB: 4L4V) [95]. (d) A hybrid δ/αβ TCR binds the CD1d-αGalCer complex. The TCR is composed of a variable Vδ1 domain fused with joining and constant α domains, and paired to a TCR-β chain. TCR-CD1d interactions are driven mainly by the germline-encoded Vδ1 residues while TCR-β mediates specific lipid recognition (PDB: 4WO4) [7]. (e) The γδ TCR recognizes CD1d-lipid complexes. Germline-encoded Vδ1 residues are responsible for CD1d binding while the lipid ligand recognition is fine-tuned by hypervariable complementarity-determining region (CDR) 3 loops (PDB: 4MNG) [92]. (f) A mouse γδ TCR binds the MHC-like molecule T22. The binding occurs predominantly via a conserved motif within the hypervariable CDR3δ loop, whereas the non-conserved CDR3δ residues fine-tune the affinity of the receptor towards T22 (PDB: 1YPZ) [96].
Similarly to ‘unconventional’ αβ TCRs, γδ TCRs can mediate recognition of lipids in the context of CD1d [92]. However, the docking manner differed substantially from type I and II NK T cells (Fig. 11e). Importantly, the contacts with CD1d were mediated mainly via germline-encoded residues in CDR1 and 2 loops, while hypervariable CDR3 loops bound the presented lipid. Therefore, it is possible that γδ TCR can distinguish between subtly different lipid cargoes bound to CD1d in an adaptive-like manner. Additionally, Willcox et al. [107] have demonstrated recently that γδ TCRs can bind a ligand shared by cytomegalovirus-infected and malignant transformed cells, namely endothelial protein C receptor (EPCR). EPCR shows homology with CD1 protein family at the level of amino acid sequence and structure, and is also capable of presenting lipids – however, the binding of the TCR to EPCR was lipid-independent (Fig. 12). The recognition was mediated via the hypervariable CDR3γ loop of the TCR, thus suggesting that EPCR binding was a part of an adaptive response rather than innate-like pattern recognition. Notably, EPCR was essential, but not sufficient, for the recognition of the target cells, highlighting the need for additional accessory molecules that would create a generalized cellular stress context. The identity of these accessory molecules on the T cell or target cell remains largely unknown.

EPCR is not the only example of a γδ TCR ligand recognized in a cellular stress context. It has been known for some time that a portion of human γδ T cells can bind MHC class I polypeptide-related sequence (MIC) A [114], a stress-related ligand of natural killer cells, and human homologue of the bacterial MutS protein (hMSH2) [115]. The best-studied set of human γδ T cells express Vγ9Vδ2 TCRs and recognize pyrophosphate antigens in the context of an immunoglobulin-like molecule, butyrophilin 3A1 [112]. The exact mechanism by which these TCRs recognize phosphoantigens awaits a TCR-ligand structure.
exciting advances are anticipated shortly. Strategies are likely to have a bright future, and further TCR-based therapeutic strategies are in development. Such half of the new drugs that come onto the market, several Although monoclonal antibodies now account for almost the identity of putative ligands remains largely unknown. Summary It has been known for several decades that the vast majority of TCRs recognize MHC-bound peptides. Recent developments have highlighted the astonishing versatility of this receptor (Fig. 12). Indeed, it is now widely accepted that a substantial fraction of T cell pool is dedicated to the recognition of non-MHC ligands. This includes recognition of various foreign lipids and metabolic intermediates and stress-related proteins. However, in the case of γδ T cells, the identity of putative ligands remains largely unknown. Although monoclonal antibodies now account for almost half of the new drugs that come onto the market, several TCR-based therapeutic strategies are in development. Such strategies are likely to have a bright future, and further exciting advances are anticipated shortly.

Acknowledgements A. K. S. and D. K. C. are Wellcome Trust Senior Investigators and Career Development Fellows, respectively. M. L. is a Cancer Research UK PhD student. Our work on TCR degeneracy is funded by the Biotechnology and Biological Sciences Research Council UK.

Disclosure The authors declare no conflicts of interest.

References

1 Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248:701–2.

2 Treiner E, Duban L, Bahram S et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 2003; 422:164–9.

3 Le Bourhis L, Martin E, Peguillet I et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol 2010; 11:701–8.

4 Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature 1994; 372:691–4.

5 Van Rhijn I, Kasmar A, de Jong A et al. A conserved human T cell population targets mycobacterial antigens presented by CD1b. Nat Immunol 2014; 14:706–13.

6 Carding SR, Egan PJ, γδ T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2002; 2:336–45.

7 Pellicci DG, Uldrich AP, Le Nours J et al. The molecular bases of δ/εβ T cell-mediated antigen recognition. J Exp Med 2014; 211:2599–615.

8 Allam A, Kabelitz D. TCR trans-rearrangements: biological significance in antigen recognition vs the role as lymphoma biomarker. J Immunol 2006; 176:5707–12.

9 Bowen S, Sun P, Livak F, Sharrow S, Hodes RJ. A novel T cell subset with trans-rearranged Vγ-Cβ TCRs shows Vβ expression is dispensable for lineage choice and MHC restriction. J Immunol 2014; 192:169–77.

10 Cole DK, Yuan F, Rizkallah PJ et al. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem 2009; 284:27281–9.

11 Allison TJ, Winter CC, Fournié JJ, Bonnevile M, Garbozzi DN. Structure of a human γmammadela T-cell antigen receptor. Nature 2001; 411:820–4.

12 Gras S, Chen Z, Miles JJ et al. Allelic polymorphism in the T cell receptor and its impact on immune responses. J Immunol 2010; 184:669–77.

13 van Boeijen H, Teh HS, Kisielow P. The thymus selects the useful, neglects the useless and destroys the harmful. Immunol Today 1989; 10:57–61.

14 Bendelac A. Positive selection of mouse NK1.1+ T cells by CD1-expressing cortical thymocytes. J Exp Med 182:2091–6.

15 T cell-mediated antigen recognition. J Exp Med 2005; 207:1555–67.

16 Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol 2012; 2:669–77.

17 Davis MM, Bjorkmann PJ. T cell antigen receptor genes and T cell recognition. Nature 1988; 334:395–402.

18 Van Boehmer H, Teh HS, Kisielow P. The thymus selects the useful, neglects the useless and destroys the harmful. Immunol Today 1989; 10:57–61.

19 Bendelac A. Positive selection of mouse NK1.1+ T cells by CD1-expressing cortical thymocytes. J Exp Med 182:2091–6.

20 Coles MC, Rautel DH. NK1.1+ T cells in the liver arise in the thymus and are selected by interactions with class I molecules on CD4+CD8+ cells. J Immunol 2000; 164:2412–8.

21 Wei DG, Lee H, Park HS et al. Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. J Exp Med 2005; 202:239–48.

22 Seach N, Guerrero L, Le Bourhis L et al. Double-positive thymocytes select mucosal-associated invariant T cells. J Immunol 2013; 191:6002–9.

23 Wilson A, de Villartay JP, MacDonald HR. T cell receptor α gene rearrangement and T early α (TEA) expression in immature αβ lineage thymocytes: implications for αβ/γδ lineage commitment. Immunity 1996; 4:37–45.

24 Coffey F, Lee SY, Buus TB et al. The TCR ligand-inducible expression of CD73 marks γδ lineage commitment and a metastable intermediate in effector specification. J Exp Med 2014; 211:329–43.
22 Turchinovich G, Hayday AC. Skint-1 identifies a common molecular mechanism for the development of interferon-γ-secreting versus interleukin-17-secreting γδ T cells. Immunity 2011; 35:59–68.

23 Jensen KD, Su X, Shin S et al. Thymic selection determines gammadelta T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma. Immunity 2008; 29:90–100.

24 Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 2015; 43:D423–31.

25 Tynan FE, Borg NA, Miles JJ et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance. J Biol Chem 2005; 280: 23900–9.

26 Mullen MM, Haan KM, Longnecker R, Jardetzky TS. Structure of the Epstein–Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. Mol Cell 2002; 9:375–85.

27 Ekeruche-Makinde J, Miles JJ, van den Berg HA et al. Peptide length determines the outcome of TCR/peptide–MHCI engagement. Blood 2013; 121:1112–23.

28 Probst-Kepper M, Hecht HJ, Herrmann H et al. Conformational restraints and flexibility of 14-meric peptides in complex with HLA-B*3501. J Immunol 2004; 173:5610–6.

29 Miles JJ, Borg NA, Brennan RM et al. TCR alpha genes direct MHC restriction in the potent human T cell response to a class I-bound viral epitope. J Immunol 2006; 177:6804–14.

30 Wynn KK, Fulton Z, Cooper L et al. Impact of clonal competition for peptide–MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection. Blood 2008; 111: 4283–92.

31 Smith KJ, Reid SW, Stuart DJ, McMichael AJ, Jones EY, Bell JJ. An altered position of the alpha 2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. Immunity 1996; 4:203–13.

32 Sliz P, Michielin O, Cerottini JC et al. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte–melanoma tumor–antigen peptide complexes. J Immunol 2001; 167:3276–84.

33 Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide–MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993; 75:693–708.

34 Siebold C, Hansen BE, Wyer JR et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci USA 2004; 101:1999–2004.

35 Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997; 7:473–81.

36 Deng L, Langley RJ, Brown PH et al. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Nat Immunol 2007; 8:398–408.

37 Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006; 24:419–66.

38 Hughes AL, Ota T, Nei M. Positive Darwinian selection promotes charge profile diversity in the antigen-binding cleft of class I major-histocompatibility-complex molecules. Mol Biol Evol 1990; 7:515–24.

39 Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev Immunol 2014; 33:169–200.

40 Miles JJ, Bulek AM, Cole DK et al. Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein–Barr virus infection. PLOS Pathog 2010; 6:e1001198.

41 Yin Y, Li Y, Kerzic MC, Martin R, Mariuzza RA. Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J 2011; 30:1137–48.

42 Merkenschlager M, Graf D, Lovatt M, Bommarth U, Zamoyra S, Fisher AG. How many thymocytes audition for selection? J Exp Med 1997; 186:1149–58.

43 Scott-Browne JP, Crawford E, Young MH, Kappler JW, Marrack P, Gapan L. Evolutionarily conserved features contribute to αβ T cell receptor specificity. Immunity 2011; 35:526–35.

44 Garcia KC, Adams JJ, Feng D, Ely LK. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol 2009; 10:143.

45 Garcia KC. Reconciling views on T cell receptor germline bias for MHC. Trends Immunol 2012; 33:429–36.

46 Deng F, Bond CJ, Ely LK, Maynard J, Garcia KC. Structural evidence for a germline-encoded T cell receptor–major histocompatibility complex interaction ‘codon’. Nat Immunol 2007; 8:975–83.

47 Stadinski BD, Trenh P, Smith RL et al. A role for differential variable gene pairing in creating T cell receptors specific for unique major histocompatibility ligands. Immunity 2011; 35:694–704.

48 Burrows SR, Chen Z, Archbold JK et al. Hard wiring of T cell receptor specificity for the major histocompatibility complex is underpinned by TCR adaptability. Proc Natl Acad Sci USA 2010; 107:10608–13.

49 Holland SJ, Bartok I, Attaf M et al. The T-cell receptor is not hardwired to engage MHC ligands. Proc Natl Acad Sci USA 2012; 109:E1111–8.

50 Yin Y, Wang XX, Mariuzza RA. Crystal structure of a complete ternary complex of T-cell receptor, peptide–MHC. Proc Natl Acad Sci USA 2012; 109:E3111–8.

51 Cole DK, Miles KM, Madura Fet al. T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR–major histocompatibility complex interactions. J Biol Chem 2013; 289: 628–38.

52 Gao GF, Torno J, Gerth UC et al. Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2. Nature 1997; 387:630–4.

53 Van Laethem F, Sarafova SD, Park JH et al. Deletion of CD4 and CD8 co-receptors permits generation of αβ T cells that recognize antigens independently of the MHC. Immunity 2007; 27:735–50.

54 Tikhonova AN, Van Laethem F, Hanada K et al. αβ T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities. Immunity 2012; 36:79–91.

55 Van Laethem F, Tikhonova AN, Singer A. MHC restriction is imposed on a diverse T cell receptor repertoire by CD4 and CD8 co-receptors during thymic selection. Trends Immunol 2012; 33:457–41.
T cell receptor versatility

56  Van Laethem F, Tikhonova AN, Pobezinsky LA et al. Lck availability during thymic selection determines the recognition specificity of the T cell repertoire. Cell 2013; 154:1326–41.

57  Rao A, Ko WW, Faas SJ, Cantor H. Binding of antigen in the absence of histocompatibility proteins by arsonate-reactive T cell clones. Cell 1984; 36:879–88.

58  Barnd DL, Lan MS, Metzgar RS, Finn Ol. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86:7159–63.

59  Hanada K, Wang QJ, Inozume T, Yang JC. Molecular identification of an MHC-independent ligand recognized by a human α/β T-cell receptor. Blood 2011; 117:4816–25.

60  Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19:395–404.

61  Wooldridge L, Ekeruche-Makinde J, van den Berg HA et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem 2012; 287:1168–77.

62  Bulek AM, Cole DK, Skowera A et al. Structural basis for the killing of human beta cells by CD8+ T cells in type 1 diabetes. Nat Immunol 2012; 13:283–9.

63  Birnbaum ME, Mendoza JL, Sethi DK et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 2014; 157:1073–87.

64  Madura F, Rizkallah PJ, Holland CJ et al. Structural basis for ineffective T-cell responses to MHC anchor residue-improved ‘heteroclitic’ peptides. Eur J Immunol 2015; 45:584–91.

65  Cole DK, Edwards ES, Wynn KK et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 2010; 185:60–10.

66  van den Berg HA, Wooldridge L, Laugel B, Sewell AK. Coreceptor CD8-driven modulation of T cell antigen receptor specificity. J Theor Biol 2009; 259:395–408.

67  Wooldridge L, Laugel B, Ekeruche J et al CD8 controls T cell cross-reactivity. J Immunol 2010; 185:4625–32.

68  Arstila T, Casrouge A, Baron V, Even J, Kanellopoulos J, Koukourakis M. A direct estimate of the human αβ T cell receptor diversity. Science 1999; 286:958–61.

69  Welsh RM, Selin IK. No one is naive: the significance of heterogeneous T-cell immunity. Nat Rev Immunol 2002; 2:417–26.

70  Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus-specific CD4+ memory-phenotype T cells are abundant in unexposed adults. Immunity 2013; 38:373–83.

71  Wucherpenning KW, Sethi D. T cell receptor recognition of self and foreign antigens in the induction of autoimmune. Semin Immunol 2011; 23:84–91.

72  Ely I, Burrows SR, Purcell AW, Rossjohn J, McCluskey J. T-cells behaving badly: structural insights into alloreactivity and autoimmunity. Curr Opin Immunol 2008; 20:575–80.

73  Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269–81.

74  Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126–9.

75  Li Y, Moysey R, Molloy PE et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 2005; 23:549–54.

76  Kieke MC, Shusta EV, Bodor ET, Teyton L, Wittrup KD, Kranz DM. Selection of functional T cell receptor mutants from a yeast surface-display library. Proc Natl Acad Sci USA 2006; 103:5651–6.

77  Hawse WF, Champion MM, Joyce MV et al. Cutting edge: evidence for a dynamically driven T cell signaling mechanism. J Immunol 2012; 188:5819–23.

78  Irving M, Zoete V, Hebeisen M et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 287:23068–78.

79  Varela-Rohena A, Molloy PE, Dunn SM et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 2008; 14:1390–5.

80  Aleksej M, Liddy N, Molloy PE et al. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 42:3174–9.

81  Cole DK, Pumphrey NJ, Boulter JM et al. Human TCR-binding affinity is governed by MHC class restriction. J Immunol 2007; 178:5727–34.

82  Tan MP, Gerry AB, Brewer JE et al. TCR binding affinity governs the functional profile of cancer-specific CD8+ T cells. Clin Exp Immunol in press 2014.

83  Cameron BJ, Gerry AB, Dukes J et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013; 5:197ra103.

84  Linette GP, Stadtmuere EA, Maus MV et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 22:863–71.

85  Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65:333–47.

86  Liddy N, Bossi G, Adams KJ et al. Monoclonal TCR-redirected tumor cell killing. Nat Med 2012; 18:980–7.

87  Sheridan C. Monoclonal T-cell receptor drugs pique pharma’s interest. Nat Biotechnol 2013; 31:950–1.

88  Mori L, De Libero G. T cells specific for lipid antigens. Immunol Res 2012; 53:191–9.

89  Birkinshaw RW, Pellicci DG, Cheng TY et al. αβ T cell antigen receptor recognition of CD1a presenting self lipid ligands. Nat Immunol 2015; 16:258–66.

90  Gadola SD, Zaccar NR, Harlos K et al. Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains. Nat Immunol 2002; 3:721–6.

91  Roy S, Ly D, Li NS et al. Molecular basis of mycobacterial lipid antigen presentation by CD1c and its recognition by αβ T cells. Proc Natl Acad Sci USA 2014; 11:E4648–57.

92  Luoma AM, Castro CD, Mayassi T et al. Crystal structure of V81 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human γδ T cells. Immunology 39:1032–42.

93  Borg NA, Wun KS, Kjer-Nielsen L et al CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007; 448:44–9.

94  Wun KS, Ross F, Patel O et al. Human and mouse type I natural killer T cell antigen receptors exhibit different fine specificities for CD1d-antigen complex. J Biol Chem 2012; 287:39139–48.
M. Attaf et al.

IMMUNOLOGY IN THE CLINIC REVIEW SERIES

95 Patel O, Kjer-Nielsen L, Le Nours J et al. Recognition of vitamin B metabolites by mucosal-associated invariant T cells. Nat Commun 2013; 4:2142.

96 Adams EJ, Chien YH, Garcia KC. Structure of a gammadelta T cell receptor in complex with the nonclassical MHC T22. Science 2005; 308:227–31.

97 Patel O, Pellicci DG, Gras S et al. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat Immunol 2007; 13:857–63.

98 Scharf L, Li NS, Hawk AJ et al. The 2.5 Å structure of CD1c in complex with a mycobacterial lipid reveals an open groove ideally suited for diverse antigen presentation. Immunity 2010; 33:853–62.

99 Lepore M, de Lalla C, Gundimeda SR et al. A novel self-lipid antigen targets human T cells against CD1c(+) leukemias. J Exp Med 2014; 211:1363–77.

100 Kjer-Nielsen L, Patel O, Corbett AJ et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012; 491: 717–23.

101 Reantragoon R, Kjer-Nielsen L, Patel O et al. Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. J Exp Med 2012; 209:761–74.

102 McWilliam HE, Birkinshaw RW, Villadangos JA, McCluskey J, Corbett AJ, Eckle SB, Birkinshaw RW et al. T-cell activation by human gamma delta T cells. Nat Immunol 2013; 14:908–16.

103 Cowan JE, Jenkinson WE, Anderson. The thymus medulla fosstion. Eur J Immunol 2015; 45:28–34.

104 Sandstrom A, Peigné CM, Léger A et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity 2014; 40:490–500.

105 Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Liber G. Human T cell receptor gammadelta cells recognize endoge nous mevalonate metabolites in tumor cells. J Exp Med 2003; 197:163–8.

106 Vavassori S, Kumar A, Wan GS et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol 2013; 14:908–16.

107 Willcox CR, Pitard V, Netzer S et al. Cytomegalovirus and human gamma delta T cells. Nature 2010; 468:857–63.

108 Uldrich AP, Le Nours J, Pellicci DG et al. CD1d-lipid antigen recognition by the γδ TCR. Nat Immunol 2013; 14:1137–45.

109 Adams EJ, Chien YH, Garcia KC. Structure of a gammadelta T cell receptor in complex with the nonclassical MHC T22. Science 2005; 308:227–31.

110 Cowan JE, Jenkinson WE, Anderson. The thymus medulla fosstion. Eur J Immunol 2015; 45:28–34.

111 Corbett AJ, Eckle SB, Birkinshaw RW et al. MR1 presentation of vitamin B-based metabolite ligands. Curr Opin Immunol 2015; 34:28–34.

112 Vavassori S, Kumar A, Wan GS et al. Butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity 2014; 40:490–500.

113 Sandstrom A, Peigné CM, Léger A et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity 2014; 40:490–500.

114 Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279:1737–40.

115 Chen H, He X, Wang Z et al. Identification of human T cell receptor gammadelta-recognized epitopes/proteins via CDR3 delta peptide-based immunobiological strategy. J Biol Chem 2008; 283:12528–37.

116 Dai Y, Chen H, Mo C, Cui L, He W. Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human γδ T cells to induce innate anti-tumor/virus immunity. J Biol Chem 2012; 287:16812–9.

117 Mo C, Dai Y, Kang N, Cui L, He W. Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. J Biol Chem 2012; 287:19242–54.

118 Lu J, Das M, Kanji S et al. Induction of ATM/ATR pathway combined with Vγ9Vδ2 T cells enhances cytotoxicity of ovarian cancer cells. Biochim Biophys Acta 2014; 1842:1071–9.

119 Xu B, Pizarro JC, Holmes MA et al. Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA. Proc Natl Acad Sci USA 2011; 108: 2414–9.

120 Bruder J, Siewert K, Obermeier B et al. Target specificity of an autoreactive pathogenic human γδ-T cell receptor in myositis. J Biol Chem 2012; 287:20986–95.

121 Aydintug MK, Zhang L, Wang C et al. γδ T cells recognize the insulin B9-23 peptide antigen when it is dimerized through thiol oxidation. Mol Immunol 2014; 60:116–28.

122 Paul S, Shlipi, Lal G. Role of gamma-delta (γδ) T cells in autoimmunity. J Leukoc Biol 2014; 97:259–71.